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Morphine and its derivatives play inevitably important role in the m-opioid receptor (MOR) targeted
antinociception. A structure-activity relationship study is presented for novel and known orvinol and
thevinol derivatives with varying 3-O, 6-O, 17-N and 20-alkyl substitutions starting from agonists, an-
tagonists and partial agonists. In vitro competition binding experiments with [3H]DAMGO showed low
subnanomolar affinity to MOR. Generally, 6-O-demethylation increased the affinity toward MOR and
decreased the efficacy changing the pharmacological profile in some cases. In vivo tests in osteoarthritis
inflammation model showed significant antiallodynic effects of thevinol derivatives while orvinol de-
rivatives did not. The pharmacological character was modelled by computational docking to both active
and inactive state models of MOR. Docking energy difference for the two states separates agonists and
antagonists well while partial agonists overlapped with them. An interaction pattern of the ligands,
involving the interacting receptor atoms, showed more efficient separation of the pharmacological
profiles. In rats, thevinol derivatives showed antiallodynic effect in vivo. The orvinol derivatives, except
for 6-O-desmethyl-dihydroetorfin (2c), did not show antiallodynic effect.
© 2020 Elsevier Masson SAS. All rights reserved., Biological Research Center,
y to this work.
served.1. Introduction
Pain modulation is mainly regulated through the activation of
the three classical types of opioid receptors, i.e. the m-, d- and k-
opioid receptors (MOR, DOR and KOR, respectively) expressed in
the neurons of the central and peripheral nervous system. The
opioid receptors are members of the G-protein coupled receptors
Scheme 1. Synthesis of 6-O-desmethyl-orvinol analogues
Figure legend: Reagents and conditions: (i): LiAlH4, CCl4, THF, reflux.
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the distinctive seven helical hydrophobic transmembrane helix
domain [1e5]. Their activation leads to the inhibition of adenylyl
cyclase which results in hyperpolarisation and inhibits neuro-
transmitter release [6,7]. The main target of the antinociceptive
drugs in the treatment of pain is MOR.
Endogenous opioid peptides such as Met- and Leu-enkephalin
[8], b-endorphin [9] and dynorphin-A [10] are produced in the
brain. Two endomorphin tetrapeptides, endomorphin-1 and
endomorphin-2 [11] were found to be highly selective endogenous
agonists for MOR. Morphine is a prototype opioid agonist binding
to MOR and is still the most frequently used drug in pain medica-
tion. Beside pain relief and analgesia, it has serious side effects
including decreased respiratory effort, low blood pressure and it
also has a high potential for addiction and abuse [12e14].Scheme 2. Synthesis of phenethyl-thevinol- and -orvinol derivatives
Figure legend: Reagents and conditions: (i): 2-phenylethymagnesium bromide, toluene-TH
CCl4, THF; reflux; (iv): BrCH2CH2F, NaH, DMF, RT, 48 h; (v): L-Selectride, THF, reflux, 3 h.Therefore, it is very important to find new ligands with higher af-
finity, selectivity and stability to get more effective drugs to
decrease the side effects.
Natural morphine alkaloids (e.g. morphine, codeine, thebaine,
neopine, oripavine) [15] can be converted into a variety of phar-
macologically more advantageous compounds, such as the so called
nal-compounds (naloxone, naltrexone, nalbuphine) and the ring-C
bridged derivatives (6,14-ethenomorphinans or Bentley-
compounds, e.g. etorphine (9), buprenorphine, diprenorphine). In
this study nine previously synthesized orvinol and thevinol-type
MOR-selective ligands [16e25] were examined (compounds 1e,
1f, 2a, 2b, 2d, 4, 5, 7, 8 (3-methoxyetorphine)). 6-O-Desmethyl-
dihydroethorphine (2c) is a new compound synthesized for this
study.
A number of structure-activity relationship studies dealing with
thevinol and orvinol derivates are available [26,27], but the
biochemical and pharmacological properties of our target com-
pounds have not been reported except for 8 [25], The aim of present
study was to compare the receptor binding properties and the
MOR, DOR and KOR selectivity of some Bentley compounds in rat
and guinea pig brain membrane preparations. The ligands were
also investigated in [35S]GTPgS functional binding assays to
examine G-protein activation via opioid receptors. The effect of the
investigated derivates was observed in vivo nociceptive tests.
The presence or absence of specific functional groups in the
orvinol and thevinol derivatives can not be straightforwardly
related to their pharmacological profiles. As an example, the 17-N-
substituent serves as an acknowledged pharmacological switch
between agonists and antagonists being methyl or cyclo-
propylmethyl, respectively. However, it is highly ambiguous within
this class of opioids, regarding that 17-N-cyclopropylmethyl de-
rivative can be full agonist as well [28,29] which may be a conse-
quence of the bigger size of these opiates resulting in a more
complex interaction pattern with the receptor. According to this, itF, 2 h; (ii): KOH diethyleneglycol, 210 C or L-Selectride, THF, reflux, 5 h; (iii): LiAlH4,
Fig. 1. MOR (A), DOR (B) and KOR (C) binding affinity of the morphine analogues
Figure legend: MOR (A), DOR (B) and KOR (C) binding affinity of morphine analogues
compared to DAMGO, Ile5,6-deltorphin II and HS665, respectively in [3H]DAMGO, [3H]
Ile5,6-deltorphin II and [3H]HS665 competition binding assays in rat (MOR, DOR) and
guinea pig (KOR) brain membrane homogenates. Membranes were incubated with
2 nM [3H]DAMGO or [3H]Ile5,6-deltorphin II for 45 min at 35 C with increasing con-
centrations (1013 - 105 M; 1010 - 105 M, respectively) or 2 nM [3H]HS665 for
30 min at 25 C (1012 - 105 M) of each competing ligand. Values represent mean
values ± S.E.M. for at least three independent experiments performed in duplicate.
E. Sz}ucs et al. / European Journal of Medicinal Chemistry 191 (2020) 112145 3seems plausible to investigate the interacting residues or atoms of
the receptor leading to the specific response, i.e. pharmacological
feature.
Former computational studies attempted to identify the inter-
acting residues in MOR responsible for different pharmacological
actions. However, no distinguishable interaction pattern was found
for a structurally highly diverse set of agonist, partial agonist andantagonist to predict pharmacological activities using the inactive
receptor state [30].
2. Results and discussion
2.1. Chemistry
In this study we report the biochemical characterization of 6-O-
desmethyl-orvinols and 20R-phenethyl-orvinols/thevinols having
(unanticipated) extremely high potency at MOR. The target com-
pounds are semisythetic thebaine derivatives and belong to the
6,14-ethenomorphinans (Bentley-compounds). The pharmacologi-
caly most important members of this opioid ligand class are
diprenorpine (1a), buprenorphine (1b), dihydroethorphine (1c),
and phenethyl-orvinol (1d). Compound 1a is an antagonist with
approximatelly the same high affinity for opioid receptor subtypes.
Compound 1b with a mixed agonist-antagonist (partial m-agonist/
k-antagonist) profile is clinicaly used as analgesic in the treatment
of postoperative and/or cancer-related pain and in the substitution
therapy of opioid dependent humans. 1c and 1d are nonselective
opioid receptor agonists.
For our pharmacological investigations, the target compounds,
18,19-dihydro-6,14-ethenomorphinans (6,14-endoethano-6,7,8,14-
tetrahydrooripavines, Scheme 1), 20R-phenethyl-orvinol and
-thevinol derivatives (Scheme 2) were synthesized from thebaine.
These compounds can be synthesized by the original method of
Bentley [21,22] or by later developed modification [31,32] of the
initial procedure starting from thebaine.
20-Methyl-orvinol (1e) [22] and 20-methyl-dihydroorvinol (1f)
were prepared as reference substances for our biological in-
vestigations. 1e was synthesized from thebaine in a three-step
procedure. The Diels-Alder adduct of thebaine and methyl-vinyl
ketone, thevinone, was reacted with methylmagnesium iodide to
give 20-methyl-thevinol. The latter was 3-O-demethylated with
KOH in diethylene glycol at 210 C to yield 1e.1fwas prepared from
dihydrothevinone in a similar manner [24].
The synthesis of 18,19-dihydro-6-O-desmethyl-6,14-
ethenomorphinan derivatives (2a-d) are depicted in Scheme 1. 6-
O-desmethyl-diprenorphine (2a) was synthesized in an eight-step
procedure from thebaine as described earlier [16]. 6-O-des-
methyl-buprenorphine (2b) was prepared analogously in an eight-
step synthesis [17]. The new etorphine derivative, 6-O-desmethyl-
dihydroetorphine (2c) was prepared in five steps. In brief, the
Grignard reaction of dihydrothevinone with n-propylmagnesium
bromide resulted in the main product 20R-dihydroetorphine-3-O-
methylether. Following 3-O-demethylation and 6-O-demethylation
2c was prepared in a 18% overall yield fom thebaine. Complete
assignments of 1H and 13C NMR spectra of the prepared compounds
are given in the Supplementary Information.
Introducing a phenyl group in the position-20 (20R-phenyl-
orvinols [nepenthone derivatives] and 20S-phenyl-orvinols [thevi-
none derivatives]) can be advantageous [33,34] while a 20-b-phe-
nethyl group results in products with extremely high affinity to
opioid receptors [35]. Phenethyl-thevinol (4) and 1d have been
playing an important role in the 1970s in the development of new
opioid receptor model [35,36]. The synthesis of phenethyl-thevinol-
and phenethyl-orvinol derivatives are demonstrated in Scheme 2.
Grignard addition of 2-phenetylmagnesium bromide to thevinone
(3) resulted in 20R-phenethyl-thevinol (4) [22],whichwas converted
either by 3-O-demethylation to 20R-phenethyl-orvinol (1d) or by 6-
O-demethylation to 6-O-desmethyl-phenethyl-thevinol (5). 6-O-
Demethylation of 1d gave 6-O-desmethyl-phenethyl-orvinol (2d).
Alkylation of 5 with 2-fluoroethyl bromide in N,N-dimethylforma-
mide in the presence of sodium hydride yielded 6-(2-fluoroethyl)-
phenethyl-thevinol (6), which was reacted with L-Selectride in THF.
Table 1
Displacement of [3H]DAMGO, [3H]Ile5,6-deltorphin II and [3H]HS665 by DAMGO, Ile5,6-deltorphin II, HS665 andmorphine derivatives inmembranes of rat and guinea pig brain.
The IC50 values for the MOR, DOR and KOR according to the competition binding curves (see Fig. 1) were converted into equilibrium inhibitory constant (Ki) values, using the
ChengePrusoff equation.
Ligand DAMGOa Ile5,6-deltorphin IIa HS665b Selectivity for m site
Ki ± S.E.M. (nM) (Kid/Kim) (Kik/Kim)
DAMGO 0.9010 ± 0.27 n.d.c n.d.c n.d.c n.d.c
Ile5,6-deltorphin II n.d.c 8.848 ± 0.77 n.d.c n.d.c n.d.c
HS665 n.d.c n.d.c 1.707 ± 0.02 n.d.c n.d.c
1a 0.2142 ± 0.30 2.11 ± 0.77 1.589 ± 0.02 9.85 7.42
1b 0.5315 ± 0.31 26.12 ± 0.77 0.280 ± 0.01 49.14 0.53
1e 0.0325 ± 0.35 37.37 ± 0.75 2.992 ± 0.03 1149.78 92.06
1f 0.4352 ± 0.28 36.56 ± 0.78 3.411 ± 0.01 84.54 7.84
2a 0.0333 ± 0.26 1.49 ± 0.71 0.024 ± 0.02 44.62 0.72
2b 0.2184 ± 0.27 15.72 ± 0.71 0.257 ± 0.01 71.96 1.18
2c 0.0136 ± 0.29 2.41 ± 0.80 0.796 ± 0.03 177.35 56.53
2d 0.0435 ± 0.29 2.06 ± 0.76 0.022 ± 0.02 47.45 0.51
4 0.0125 ± 0.30 7.73 ± 0.77 2.186 ± 0.02 618.30 174.88
5 0.0063 ± 0.27 1.85 ± 0.75 0.321 ± 0.03 294.43 50.95
7 0.2524 ± 0.25 27.53 ± 0.75 0.682 ± 0.02 109.06 2.70
8 0.3260 ± 0.30 3906.3 ± 0.84 7.636 ± 0.01 11982.52 23.42
9 0.1771 ± 0.30 2.44 ± 0.81 1.443 ± 0.01 13.78 8.15
a Rat brain membrane.
b Guinea pig brain membrane.
c Not determined.
E. Sz}ucs et al. / European Journal of Medicinal Chemistry 191 (2020) 1121454Unexpectedly, 6-O-ethyl-6-O-desmethyl-phenethyl thevinol (7) was
isolated from the product mixture as solely product in 90% as result
of reductive defluorination.
In the present study we performed a selective 6-O-demethyla-
tion of several compounds in order to study the structure-activity
relationships. Binding affinities of 6-O-desmethyl-orvinols to
opioid receptors were not yet investigated and their pharmaco-
logical/biochemical characterisation is currently not available in the
scientific literature. In contrast to 3-O-demethylation the 6-O-
demethylation of Bentley compounds is less explored. 6,14-Fig. 2. The effect of morphine analogues on G-protein activity compared to the parent liga
Figure legend: “Total” on the x-axis indicates the basal activity of the monitored G-protein,
binding of [35S]GTPgS. The level of basal activity was defined as 100% and it is presented with
in triplicate.Ethenomorphinans with a free tertiary hydroxyl group in
position-6 were inaccessible before 1986. The first selective 6-O-
demethylation of 7a-aminomethyl- and 7a-aldoxime-type 6,14-
ethenomorphinan derivatives was reported by Kopcho &
Schaeffer [37]. Lithium aluminium hydride in tetrahydrofuran
containing a halogenated co-solvent (CCl4) was utilized as deme-
thylating system. A six membered ring aluminum complex was
hypothesized to play an important role in this unusual O-deal-
kylation. Subsequently, Lever et al. [16,17] extended this special 6-
O-demethylation method for other 6,14-ethenomorphinans withnds in [35S]GTPgS binding assays in rat brain membrane homogenates.
which is measured in the absence of the ligands and also represents the total specific
a dotted line. Points represent means ± S.E.M. for at least three experiments performed
Table 2
The maximal G-protein efficacy (Emax) of the morphine analogues in [35S]GTPgS
binding assays in rat brain membrane homogenates. The values were calculated
according to dose-response binding curves in Fig. 2.
Ligand Potency
log EC50 þ S.E.M. (M)
Efficacy
Emax ± S.E.M. (%)
1a n.d.a 98.65 ± 1.40
1b 5.96 ± 0.22 135.98 ± 5.03
1e 6.39 ± 0.26 128.31 ± 3.18
1f n.d.a 102.87 ± 1.59
2a n.d.a 101.31 ± 0.98
2b n.d.a 100.81 ± 0.73
2c 7.77 ± 0.21 134.71 ± 2.05
2d 9.02 ± 0.11 149.46 ± 1.28
4 8.99 ± 0.14 155.09 ± 1.83
5 8.71 ± 0.15 150.95 ± 2.10
7 6.94 ± 0.12 142.64 ± 2.00
8 7.09 ± 0.17 135.32 ± 2.07
9 8.01 ± 0.09 148.61 ± 1.41
a Not determined.
Fig. 3. Stimulation of G-protein activation in rat brain membrane homogenates.
Figure legend: blue, 10 mM morphine analogues alone; green, 10 mM morphine ana-
logues and equimolar antagonist 1a; red, 10 mM morphine analogues and equimolar
full agonist 9 (A). The decrease of the effect of 9 by partial agonists in [35S]GTPgS
binding assays (B). . (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
E. Sz}ucs et al. / European Journal of Medicinal Chemistry 191 (2020) 112145 5tert-alcohol functions in the position-20. Anothermethod for the 6-
O-demethylation of 6,14-ethenomorphinans has been developed
by Breeden et al. [38], in 1999.
2.2. In vitro studies
2.2.1. Competition binding assay
Opioid receptor binding affinities of the analogues were exam-
ined in [3H]DAMGO, [3H]Ile5,6-deltorphin II and [3H]HS665 ho-
mologous displacement experiments for MOR, DOR and KOR,
respectively, in rat and guinea pig brain homogenates. All de-
rivatives exhibited higher binding affinity in m-opioid receptor
system than the selective peptide ligand DAMGO (Fig. 1A), some of
them had extremely low Ki values (Table 1). For DOR the ligands
showed comparable binding affinities than the selective DOR
agonist Ile5,6-deltorphin II peptide ligand (Fig. 1B) except 8
(Ki > 3000 nM). In the KOR binding assays, performed in guinea pig
brain membranes, the analogues still displayed nanomolar affin-
ities (Fig. 1C).
2.2.2. Functional GTPgS binding stimulation assay
The effect of the ligands on receptor-mediated G-protein acti-
vation was investigated in [35S]GTPgS binding assays in rat brain
membranes (Fig. 2). The highest stimulations were observed with
2d, 4, 5, 7 and 9, therefore they can be considered as full agonists.
1a, 1f, 2a and 2b did not produced dose-dependent increases, so
they behave as neutral or pure antagonists (Table 2). The remaining
compounds (1b, 1e, 2c and 8) exhibiting intermediate levels of G-
protein activation are partial agonist ligands in this in vitro system.
The pure opioid antagonist 1a successfully reversed the efficacy
of almost all compounds to basal activity with the exception of 2d
which showed some remaining activation in the presence of
equimolar 1a. Maximal stimulation produced by the ligands was
mostly not elevated further when the full agonist 9 was co-
administered (Fig. 3A). However, in the case of 1f and 2b the co-
presence of 9 was able to effectively stimulate G-protein activa-
tion (Table 3).
Increasing concentrations of the partial agonists were also
investigated in the presence of 10 mM 9 producing maximal stim-
ulation (Fig. 3B). All four compounds were able to inhibit the acti-
vation mediated by 9, although with relatively low efficacy and
potency. This weak antagonizing effect in the presence of a full
agonist validates that 1b, 1e, 2c and 8 are indeed partial agonist
ligands for opioid receptors (Table 3).
2.3. In vivo studies
The basal withdrawal threshold of the non-inflamed side was
45 ± 0.5 g, and MIA caused significant decrease in paw withdrawal
threshold on the injected side (24 ± 0.6 g). Only the largest dose of 9
treatments caused significant enhancement in the pain threshold
on the non-inflamed side, therefore, results were analysed only on
the inflamed paws. The different ligands showed different po-
tencies, therefore, they were compared to distilled water (as
negative control) in the ANOVA analysis, but the curve for 9 was
also demonstrated as a positive control group with the lowest ED30
value (Table 4).
All of the thevinol derivatives showed significant antiallodynic
effects (Fig. 4); however, the regression analysis revealed a lower
in vivo potency compared to 9 as indicated by the ED30 values, even
it could not be calculated for 7 (Table 4). Regarding 4, the treatment
was close to significant (Table 4). Time and their interaction
showed significant effects, and the post-hoc analysis showed
decreased allodynia in several time-points compared to the control
group (Fig. 4A). ANOVA for repeated measurements showed
Table 3
The maximal G-protein efficacy (Emax) the morphine analogues in the absence or presence of the opioid antagonist and agonist, 1a and 9, respectively in rat brain membrane
homogenates. The values were calculated according to dose-response binding curves in Fig. 3.
Ligand
Efficacy
Emax ± S.E.M. (%)
10 mM ligand 10 mM ligand þ10 mM of 1a 10 mM ligand þ10 mM of 9 Ligand (1010-105 M)
þ10 mM of 9
1a 100.45 ± 3.05 e e e
1b 135.17 ± 0.82 99.30 ± 3.70 135.93 ± 0.58 136.20 ± 1.20
1e 133.27 ± 7.67 101.25 ± 6.45 129.45 ± 1.85 129.45 ± 0.61
1f 104.63 ± 2.00 100.25 ± 1.75 135.20 ± 0.00 e
2a 97.90 ± 2.75 98.10 ± 0.90 101.00 ± 0.00 e
2b 96.50 ± 3.47 101.20 ± 3.40 128.10 ± 0.00 e
2c 135.90 ± 0.30 94.40 ± 4.20 135.50 ± 0.95 136.80 ± 0.58
2d 150.80 ± 1.20 125.30 ± 7.80 151.40 ± 0.00 e
4 158.75 ± 5.15 99.30 ± 2.10 153.20 ± 0.00 e
5 156.20 ± 0.10 102.40 ± 6.90 155.80 ± 0.00 e
7 145.45 ± 2.05 101.05 ± 5.95 149.20 ± 0.00 e
8 136.77 ± 3.67 102.60 ± 6.90 135.63 ± 0.79 135.10 ± 0.87
9 152.15 ± 0.85 100.50 ± 3.00 e e
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post hoc comparison revealed that only the highest doses caused
significant antiallodynic effect with similar efficacy as 9 (Fig. 4B).
Similarly, 7 treatment also showed significant effects, and the post
hoc comparison revealed significant increase in pain threshold at
several time points after the highest dose compared to the control
group (Fig. 4C).
Regarding 2a and 2b treatments, there were no significant ef-
fects and ED30 values could not be calculated (Fig. 5A and B,
Table 4). However, 2c administration resulted in significant effects
of treatment, time, and their interaction, with a relatively low ED30
value (Table 4). The post hoc comparison revealed that the largest
dose of 2c caused similar degree of antiallodynic effect as did 9;
evenmore prolonged effect was observed (Fig. 5C).1e,1f and 2d did
not produce significant antinociceptive effects (Fig. 5D, E, F), and
ED30 values could not be calculated either.2.4. In silico studies
2.4.1. Docking
Almost all of the investigated compounds showed higher
binding affinity to MOR and thus they are expected to exert G-
protein activation through MOR. According to this, their pharma-
cological behaviour was modelled on the MOR crystal structures.Table 4
The applied drugs and the cumulative dose procedure, the number of the animals and AN
(CI).
Drug Doses (nmol/kg) ED30 (CI) nmol/kg
0.1 0.3 1.0 3.0 10.0 N
Distilled water 6
1e þ þ þ 7
1f þ þ þ 8
2a þ þ þ 8
2b þ þ þ 7
2ca þ þ þ 6 4.5 (2.59e6.11)
2cb þ þ þ 6
2d þ þ þ 8
4 þ þ þ 7 8.0 (5.16e10.88)
5a þ þ þ 6 7.2 (5.11e9.35)
5b þ þ þ 7
7 þ þ þ 8 uncountable
9 þ þ þ 6 0.1 (0.01e0.49)
a Dose: 0.3-1-3 nmol/kg.
b Dose: 1-3-10 nmol/kg.The target compounds aremembers of three pharmacological types
showing agonism, antagonism or partial agonism at MOR. Thus the
target compounds and several known agonists, antagonists and
partial agonists, composing a set of 48 compounds (Tables S3e1,
Tables S3e2) [25,26,28,29,39], were docked to both the active and
inactive receptor models to reveal whether their characteristics in
docking experiments can be related to that of ligands with known
pharmacological character. However, a simple visual inspection of
the docked positions did not reveal specific features to explain the
pharmacological diversity neither at the active nor at the inactive
receptor state, therefore, the ligands were further characterized
with their docking energies and the contacting receptor atoms. It is
noteworthy that among the lowest energy docking poses only 16
out of 96 (48 ligands docked to both receptor states) originated
from energy minimized conformers (see Experimental section
4.4.3.) suggesting the role of the flexibility of aliphatic rings.2.4.2. Analysis of the docking energies and ligand efficiencies
obtained for the active and inactive receptor states
Three kinds of docking energy measures were investigated:
docking energies calculated by AutoDock Vina (E), ligand efficiency
(docking energy divided by the number of non-hydrogen atoms of
the ligand, LE) [40] and a similar value obtained from the docking
energy divided by the count of the interacting atoms of the ligandOVA results in each group and their in vivo potency as ED30 with confidence interval
ANOVA
Group Time Interaction
NS NS NS
NS NS NS
NS NS NS
NS NS NS
NS 10,100 ¼ 2.11 p < 0.05 NS
1,100 ¼ 15.48 p < 0.005 10,100 ¼ 2.96 p < 0.005 10,100 ¼ 3.42 p < 0.001
NS NS NS
1,110 ¼ 4.50 p ¼ 0.06 10,110 ¼ 2.21 p < 0.05 10,110 ¼ 2.85 p < 0.005
NS NS NS
1,110 ¼ 5.02 p < 0.05 10,110 ¼ 2.61 p < 0.01 10,110 ¼ 3.30 p < 0.001
1,120 ¼ 5.32 p < 0.05 NS NS
1,100 ¼ 20.80 p < 0.005 10,100 ¼ 3.03 p < 0.005 10,100 ¼ 2.05 p < 0.05
Fig. 4. The effects of thevinol derivates in behavioral nociceptive test. Arrows indicate the time points of cumulative drug administrations. * signs p < 0.05 from control group.
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measures was analysed by two-sided paired t-tests (Table 5.). Ac-
cording to this, agonists and partial agonists clearly differentiate
between the receptor states by docking energies and LE while an-
tagonists do not. In case of LEIAC agonists could not distinguish the
receptor states. The energetic preference of the different ligand
types for the receptor states, i.e. the difference between the docking
energies obtained for the active and inactive states, was also
investigated (Table S4). The energy differencewould be negative for
agonists showing their physically feasible preference for the active
receptor and it should be the opposite (positive) for antagonists.
Although this expectation was only partially fulfilled within the
series of compounds investigated here, agonists were well sepa-
rated from antagonists and partial agonists by two-sided unpaired
t-tests using docking energy and LE values (Table 6.). Antagonists
and partial agonists did not differ significantly. This is an interesting
result however, because the geometric differencies between the
receptor states do not seem significant (Table S5, Fig. S23), never-
theless the ligands distinguished them by binding energy.
2.4.3. Multivariate statistical analysis of docking energy values
Because both the receptor preference of the ligand types
(Table 5.) and the difference between the types (Table 6.) were
partially fulfilled, principal component analysis (PCA) was per-
formed with five principal components to reveal the relationships
between docking energy values and pharmacological features.
Input data were the docking energies (E), LE and LEIAC values and
their differences for the two receptor (Table S4). Additionally, the
energy contributions decomposed for the specific interacting atom
pair types, calculated by BINANA, were also involved. The different
energy measures, however, did not contribute equally well in PCAto separate the experimentally determined pharmacological types.
The efficiency of clustering was assessed by considering hierar-
chical clustering, J2 statistics [41] and pairwise cluster overlap
statistics using the program package “pca-utils” [42] for the five
PCA components. Hierarchical clustering statistics and pairwise
cluster overlap probabilities conformed each other showing that
the separation of agonists from antagonists and partial agonists
performed well while distinguishing antagonists from partial ag-
onists highly depended on the energy measures used in PCA
(Table 7. J2 statistics). J2 measures the fuzziness of the clusters, less
J2 means more compact cluster. It is interesting that using the
decomposed energy contributions (ES) resulted in more efficient
cluster separation but less compact clusters (Table 7. J2 statistics,
cluster overlapping statistics). Considering all three quality matrix,
the best classification was obtained by the use of the docking en-
ergies and their active-inactive receptor differences (Ea, Ei, Ea-Ei,
LEa-LEi, LEIACa-LEIACi). Results for the first two PCA dimensions
and the distance matrix for five PCA variables are shown in (Fig. 6).
The results show that the ligands can be classified to their known
pharmacological groups using docking energies and related mea-
sures, albeit with significant overlap (Fig. 6A). However, a closer
look on 3D representation of the first three PCA dimensions (Fig. 7)
revealed better separation of the ligand types. There is a little
overlap between agonists and antagonists while partial agonists
overlap with both. According to PCA results 2c, a newly synthesized
partial agonist, is among antagonists and close to established par-
tial agonists (BU08028 (11), BU61 (14)). However, 1f, despite being
antagonist experimentally, showed up among agonists in all kinds
of PCA calculations. Furthermore, compound 30, considered to be a
full agonist despite its N-cyclopropylmethyl substituent [29], was
among antagonists in this model. It is worth to note that the use of
Fig. 5. The effects of orvinol derivates in behavioral nociceptive test. Arrows indicate the time points of cumulative drug administrations. * signs p < 0.05 from control group.
Table 5
Paired t-test/Welch-test of docking energies for active and inactive receptors.
Ligand type F-test t-test
Agonists 0.632 7.89  1012
Antagonists 0.545 0.227
Partial agonists 0.192 0.008
Table 6
Comparison of docking energy differences between ligand types.
Ligand types F-test t-test
agonist - antagonist 0.020 2.00  105*
agonist - partial agonist 0.023 2.98  104*
partial agonist - antagonist 0.845 0.371
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efficiency.2.4.4. Characterization of the ligands by the interacting receptor
atoms
Because the ligands exert their effects through interactions with
the receptor, the details of these interactions (interaction pattern)
Table 7
Assessment of ligand type classification by PCA.
VARIABLES Dendogram statistics J2 statistics Overlap probabilities
AG vs. (PAG, ANTAG) PAG vs. ANTAG AG PAG ANTAG AG e PAG AG e ANTAG PAG e ANTAG
Ediffs* 1.20E-03 0.72 2.02 7.44 6.45 2.81E-03 3.13E-04 7.24E-01
E,LE* 9.30E-04 0.53 42.77 32.37 1.28 6.24E-04 1.03E-03 5.32E-01
E,LE,LEIAC* 5.10E-03 0.54 2.11 21.44 2.10 6.87E-03 2.61E-03 5.38E-01
E,ES* 0.01 0.02 0.87 915.79 8.79 8.55E-03 1.44E-02 2.33E-02
E,LE,ES* 9.50E-03 0.04 0.82 900.51 9.44 7.68E-03 9.14E-03 3.80E-02
E,Ediffs 7.90E-03 0.81 6.75 5.46 22.13 1.45E-02 2.85E-03 8.08E-01
E,LEIAC* 3.50E-03 0.9 2.67 4.42 2.06 7.97E-03 9.28E-04 9.01E-01
E,LE,LEIAC,
Ediffs*
5.30E-03 0.54 2.13 21.68 2.15 7.29E-03 2.63E-03 5.38E-01
E,LE,LEIAC,
Ediffs,ES*
1.00E-03 0.06 1.23 899.80 9.45 3.70E-03 1.54E-04 6.14E-02
atomname,sd,a,i** 1.00E-04 0.01 8.16 171.02 5.75 1.91E-04 3.07E-05 1.32E-02
atomname,sd,a** 1.90E-04 8.30E-03 6.52 508.23 1.88 4.04E-04 5.06E-05 8.28E-03
atomname,sd,i** 1.50E-04 0.05 2.19 20.43 70.44 8.78E-04 1.37E-05 4.65E-02
atomname** 2.20E-05 0.02 58.60 2805.44 1.24 1.55E-04 1.64E-06 1.53E-02
residue,sd** 4.80E-03 0.1 37.01 633.30 0.72 3.19E-03 5.48E-03 9.90E-02
AG: agonist, PAG: partial agonist, ANTAG: antagonist, *: PCA, **: MCA, a: active receptor state, i: inactive receptor state, sd: stabilizing/destabilizing interaction types involved,
atom: atom based interaction pattern, residue: residue level interaction pattern.
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a ligand is the list of the interacting receptor atoms depicted in both
receptor states. Additionally, each atom is marked whether it was
involved in stabilizing (attractive) and/or destabilizing (repulsive)
interaction. The interacting receptor atomswere extracted from the
output of BINANA [43] analysis of the receptor-ligand complex
listing up all particular interacting ligand-receptor atom pairs using
the default parameters of BINANA. The stabilizing/destabilizing
nature of an interaction between the ligand and receptor depends
on the type of the interacting atoms. There are compatible and
incompatible atom types (or atom classes) [44] resulting in stabi-
lizing and destabilizing interactions, respectively. The atom class
schemewas adopted to the AutoDock atomtypes from Sobolev et al.
[44]. The classification of the ligands using their interaction pat-
terns was performed bymultiple correspondence analysis (MCA). A
variety of interaction patterns, holding different information of the
interactions, were created to find the most useful one for phar-
macological classification of the ligands: i) both receptors, indi-
vidual atoms, stabilization flags, ii) active receptor, individual
atoms, stabilization flags, iii) inactive receptor, individual atoms,
stabilization flags, iv) both receptors, individual atoms, without
stabilization flags, v) both receptors, residues only, stabilizationFig. 6. Classification of the compounds by PCA of the docking energy measures
Figure legend: Individuals scores plot in the first two principal components (A), distance mflags. As it was expected, the best classification was obtained with
the most information rich input, i.e.with both receptors, individual
atoms, stabilization flags (i) and the worst separation was obtained
using only the interacting residues and stabilization flags (Table 7
J2). The MCA results are shown in Fig. 8 and the 3D representa-
tion in Fig. 9.
Comparing the energy based PCA and the interaction pattern
basedMCA results suggests that the interaction patterns resulted in
better pharmacological classification of the ligands, although the
antagonist 1f was an outliner in both cases being close to the
agonist group. It is worth to note that the cluster separation sta-
tistics was better for all kinds of MCA results compared with PCA,
although the fuzziness of the clusters increased (Table 7).
Biological properties of our thirteen synthetic morphine ana-
logues were investigated by in vitro biochemical and in vivo phar-
macological experiments. In radioligand binding assays performed
usingMOR-, DOR- or KOR-selective [3H]labelled primary ligands, all
analogues exhibited excellent affinities for the multiple types of
opioid receptors. At the MOR binding sites 2c, 4 and 5 were the
most potent ligands, but all of the remaining compounds repre-
sented quite high affinities. They were also potent competitors in
the DOR-selective receptor binding assays, displaying stillatrix calculated with five principal components (B).
Fig. 7. Stereo view of 3D scores plot of PCA of the docking energy measures
Figure legend: red: agonists, green: antagonists, blue: partial agonists. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of
this article.)
Fig. 8. Classification of the compounds by MCA of the interaction pattern
Figure legend: A: Individuals scores plot in the first two principal components, B: distance matrix calculated with five principal components.
Fig. 9. Stereo view of 3D scores plot of MCA of the docking interaction pattern
Red: agonists, green: antagonists, blue: partial agonists. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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exception of 8which had only moderate affinity for DOR. 2a and 2d
showed the highest affinities at KOR ligand binding sites, although
all other analogues produced low nanomolar binding affinities.
Taken together, the thevinol and orvinol derivatives are very high
affinity opioid ligands, with a general preference for
MOR > KOR > DOR binding sites.
Receptor mediated G-protein activation experiments were con-
ducted in vitro using rat brain membrane preparations and [35S]
GTPgS binding stimulation assays. Transmembrane signalling prop-
erties of the compounds were variable, and the ligands used can be
divided into three biochemical pharmacological groups based on
their stimulation features. Full agonists, such as 2d, 4, 5, 7 and 9
produced the highest efficacy (Emax values) and they can be char-
acterised by culminating sigmoid stimulation curves with a plateau.
Partial agonist ligands, 1b, 1e, 2c and 8, exhibited submaximal effi-
cacies and rather decreased potencies in activating Gi/Go regulatory
proteins. Another previous term for partial agonists has been mixed
agonist-antagonist ligands. When both a full agonist and partial
agonist are present, the partial agonist actually acts as a competitive
antagonist, competing with the full agonist for receptor occupancy
and producing a net decrease in the receptor activation observed
with the full agonist alone (Fig. 6B). The third cluster of ligands are
pure or neutral opiate antagonists, such as 1a, 2a, 2b and 1f. They are
characterised by horizontally linear dose-response curves indicating
no changes in the basal G-protein activity.
6-O-demethylation usually increased the binding affinity to
MOR (1a vs. 2a, 1b vs. 2b, 2c vs. 9, 4 vs. 5). In accordance with this
finding, increasing the size of the 6-O-substituent (4 vs. 7)
decreased the binding affinity to MOR (Table 1). The opposite trend
was observed for the efficacy in some cases, resulting in a shift of
the pharmacological profiles, i.e. from partial agonist to antagonist
(1b vs. 2b), from agonist to partial agonists (2c vs. 9). In the phe-
nethyl thevinol series (2d, 4, 5, 7) 6-O-demethylation did not
decrease the efficacy. On the contrary, the bigger 6-O-substituent in
7 slightly decreased the efficacy, however, it still can be considered
as a full agonist (Table 3). The changes in the pharmacological
features caused by the different substituents are graphically sum-
marized in Fig. S37.
Behavioural nociceptive properties of the ligands were studied
in vivo, using Wistar rats in a chronic osteoarthritic inflammatory
pain model. 9 at cumulative doses of 0.1-0.3e1.0 nmol/kg remained
the most effective compound in decreasing inflammatory pain. 2c,
4 and 5, which exhibited the highest ligand binding affinities at the
MOR, produced less antinociception than 9 did. The other full (2d)
or partial antagonists (1e, 7), as well as the two neutral antagonists
2a and 2b examined in this test were practically not effective even
in ten times higher (1-3-10 nmol) cumulative doses.
Docking the ligands to both the active and inactive receptor
states makes possible reasonable pharmacological classification of
the ligands by docking energies. The positive effect of the differ-
ences of the docking energy measures on the pharmacological
classification of the ligands also emphasize that, despite the mod-
erate geometric difference between the active and inactive receptor
states within the binding pocket, the docking energies can predict
the pharmacological features of the ligands. Pharmacological clas-
sification was also attempted by the interaction pattern of the
docked ligands, i.e. by the interacting receptor atoms and the type
of the interactions (stabilizing or distabilizing). More information
(i.e. more kinds of docking energy measures, two receptor states
instead of single one) resulted in better classification in both cases.
Agonists and antagonist are separated quite well while partial
agonists overlap with the others which is in accordance with mo-
lecular dynamics results comparing interactions of agonists, an-
tagonists and partial agonists; nevertheless, pharmacologicalclassification by the docking algorithm in the present paper is still
closer to the high throughput methodology.
3. Conclusions
All investigated compounds showed subnanomolar binding af-
finity to MOR and a preference to MOR over DOR and KOR. The
pharmacological effects of the compounds involved agonism, par-
tial agonism and antagonism. Neither binding affinities nor phar-
macological features could be directly related to particular organic
functional groups.
The in vitro pharmacological effects and the in vivo antiallodynic
effects were in accordance except the full agonist 2d. As the only
exception, the newly synthesized compound, 2c despite its partial
agonist feature, showed antiallodynic effect equal tot hat of the full
agonist 9.
Due to the harmony between the in vitro and in vivo results, the
in silico calculations were expected to explain the pharmacological
profiles of the compounds. The unsupervised multivariate classifi-
cation methods (using either docking energies or interaction fin-
gerprints) applied to the docking results, obtained from active and
inactive receptor states, were able to separate the agonists from
antagonists with a good accuracy. Additionally, the third group,
partial agonists, were partially differentiated from the other two
groups. Due to the effectivity of the multivariates classification,
their further improvement seems to be promising. Differentiating
between ORs needs accurate docking calculations, however, if it is
accurate enough it can differentiate between the receptor states as
well. If it is so, the first step in the modelling scenario should be the
pharmacophoric featuring (receptor state selection) for binding
affinity prediction.
4. Experimental section
4.1. General procedure
Reagents and solvents were obtained from commercial sup-
pliers and were used without further purifications. Melting points
were measured with a Büchi-535 instrument and the data are
uncorrected. Column chromatography was performed on Kieselgel
60 Merck 1.09385 (0.040e0.063 mm). Analytical TLC was accom-
plished on Macherey-Nagel Alugram® Sil G/UV254 40  80 mm
aluminium sheets [0.25 mm silica gel with fluorescent indicator]
with the following eluent systems (each (v/v)): [A]: chloroform-
methanol 9:1, [B]: ethyl acetate-methanol 8:2, [C]: hexane-ethyl
acetate 7:3, [D]: hexane-ethyl acetate 1:1. The spots were visual-
ized with a 254 nm UV lamp or with 5% phosphomolybdic acid in
ethanol.
NMR spectra: All the 1D and 2D NMR experiments were recor-
ded on a Bruker AV 500 (Avance 500 MHz) spectrometer at 298 K,
using BBO probehead (hp workstation xw 5000, software: Bruker
TOPSPIN 1.3). For 1H experiment: 10 mg of the appropriate orvinol
was dissolved in 500 mL of deuterated chloroform (CDCl3). For
measuring 13C NMR spectra: 20 mg sample of the corresponding
derivative was dissolved in 500 mL CDCl3. Chemical shifts (d) are
reported in parts per million (ppm), and coupling constants (J) re-
ported in Hertz. 1H and 13C NMR chemical shifts were referenced to
the residual peak of CDCl3 at d 7.26 and 77.16 ppm, for proton and
carbon, respectively.
4.1.1. General procedure for the 3-O-demethylation of thevinol
derivatives (preparation of 1e, 1f and 1d)
Potassium hydroxide (3.2 g, 57 mmol) was dissolved in dieth-
ylene glycol (20 mL) at 110 C. The solution was allowed to cool to
70 C and the corresponding 3-O-methyl-thevinol derivative
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atmosphere at 210 C (internal temperature) for 90 min. The
brownish product mixture was allowed to cool to room tempera-
ture and poured into a saturated ammonium chloride solution
(40 mL). The suspension was extracted with diethyl ether
(4 45mL). The combined organic layer was extracted successively
with 5% sodium hydrogen sulfite solution (2  30 mL) and water
(2  30 mL). The organic phase was dried (Na2SO4) and the solvent
was evaporated under reduced pressure. The residue was purified
by means of column chromatography on silica gel using the
appropriate solvent system.
1d: prepared from 20R-phenethyl-thevinol (4, 975 mg, 2 mmol).
Eluent system: hexane-ethyl acetate 8:2 (v/v). Yield: 590 mg (62%).
4.1.1.1. (5R,6R,7R,9R,13S,14S)-4,5-Epoxy-3-hydroxy-a,a,17-trimethyl-
6,14-ethenomorphinan-7-methanol (1e). 1e was synthesized from
20-methyl-thevinol (795 mg, 2 mmol). Eluent system: chloroform-
methanol 9:1 (v/v). Yield: 440 mg (57%). 1H NMR (CDCl3) d ¼ 0.77
(dd, 2J8a,8b¼ 12.9 Hz, 3J8a,7b¼ 8.2 Hz,1H, 8a-H), 1.01 (s, 3H, 20-CH3),
1.08 (s, 3H, 20-CH3), 1.84 (dd, 2J15eq,15ax ¼ 13.1 Hz,
3J15eq,16ax ¼ 2.6 Hz, 1H, 15-Heq), 1.96 (app t, 3J7b,8a ¼ 8.8 Hz, 1H, 7b-
H), 1.99 (td, 2J15ax,15eq¼ 13.1 Hz, 3J15ax,16eq¼ 5.7 Hz, 1H,15-Hax), 2.36
(m, 1H, 10a-H), 2.37 (s, 3H, NCH3), 2.41 (m, 1H, 16-Hax), 2.52 (dd,
2J16eq,16ax ¼ 12.1 Hz, 3J16eq,15ax ¼ 5.3 Hz, 1H, 16-Heq), 2.87 (ddd,
2J8b,8a ¼ 12.9 Hz, 3J8b,7b ¼ 9.1 Hz, 1H, 8b-H), 3.12 (d, 3J9a,10a ¼ 6.5 Hz,
1H, 9a-H), 3.20 (d, 2J10b,10a ¼ 18.5 Hz, 1H, 10b-H), 3.75 (s, 3H, 6-
OCH3), 4.50 (br s, 1H, 3-OH), 4.57 (s, 1H, 5b-H), 4.77 (br s, 1H, 20-
OH), 5.42 (d, 3J19,18 ¼ 9.1 Hz, 1H, 19-H), 5.93 (d, 3J18,19 ¼ 9.1 Hz, 1H,
18-H), 6.47 (d, J1,2 ¼ 8.2 Hz, 1H, 1-H), 6.59 (d, J2,1 ¼ 8.2 Hz, 1H, 2-H).
13C NMR (CDCl3) d ¼ 22.2 (C-10), 25.2 (20CH3), 28.6 (20CH3), 30.9
(C-8), 33.4 (C-15), 42.9 (C-14); 43.5 (NCH3), 45.5 (C-16), 47.5 (C-13),
48.5 (C-7), 55.1 (6OCH3), 59.9 (C-9), 73.5 (C-20), 84.1 (C-6), 99.2 (C-
5), 116.0 (C-2), 119.6 (C-1), 124.4 (C-18), 127.9 (C-11), 134.0 (C-12),
135.3 (C-19), 137.2 (C-3), 146.5 (C-4). HRMS (TOF): Calcd. for
C23H29NO4 [MþH]þ: 384.2169; Found: 384.2178.
4.1.1.2. (5R,6R,7R,9R,13S,14S)-4,5-Epoxy-18,19-dihydro-3-hydroxy-
a,a,17-trimethyl-6,14-etheno morphinan-7-methanol (1f). 1f: pre-
pared from 20-methyl-dihydrothevinol (800 mg, 2 mmol). Eluent
system: chloroform-methanol 9:1 (v/v). Yield: 470 mg (60%). 1H
NMR (CDCl3) d ¼ 0.75 (m, 1H, 19-Hsyn), 1.02 (m, 1H, 19-Hanti), 1.08
(dd, 2J8a,8b¼ 12.8 Hz, 3J8a,7b¼ 9.2 Hz, 1H, 8a-H), 1.18 (s, 3H, 20-CH3),
1.37 (s, 3H, 20-CH3), 1.66 (dd, 2J15eq,15ax ¼ 13.2 Hz,
3J15eq,16ax ¼ 2.6 Hz, 1H, 15-Heq), 1.75e1.78 (m, 2H, 18-Hanti, 18-Hsyn),
1.91 (app t, 3J7b,8a ¼ 9.2 Hz, 1H, 7b-H), 2.04 (td, 2J15ax,15eq ¼ 12.7 Hz,
3J15ax,16eq ¼ 5.4 Hz, 1H, 15-Hax), 2.20 (dd, 2J10a,10b ¼ 18.3 Hz,
3J10a,9a¼ 6.2 Hz, 1H, 10a-H), 2.30 (m,1H, 16-Hax), 2.31 (s, 3H, NCH3),
2.44 (dd, 2J16eq,16ax¼ 11.9 Hz, 3J16eq,15ax¼ 5.2 Hz,1H,16-Heq), 2.65 (d,
3J9a,10a ¼ 6.2 Hz, 1H, 9a-H), 2.78 (ddd, 2J8b,8a ¼ 12.6 Hz,
3J8b,7b ¼ 11.3 Hz, 4J8b,19syn ¼ 1.1 Hz, 1H, 8b-H), 3.10 (d,
2J10b,10a ¼ 18.3 Hz, 1H, 10b-H), 3.52 (s, 3H, 6-OCH3), 4.42 (s, 1H, 5b-
H), 5.05 (br s, 1H, 20-OH), 7.07 (br s, 1H, 3-OH), 6.53 (d, J1,2 ¼ 8.0 Hz,
1H,1-H), 6.69 (d, J2,1¼8.0 Hz,1H, 2-H); 13C NMR (CDCl3) d¼ 17.4 (C-
18), 21.9 (C-10), 24.8 (20CH3), 29.7 (C-19), 29.8 (20CH3), 32.3 (C-8),
35.4 (C-15), 36.0 (C-14); 43.4 (NCH3), 45.1 (C-16), 46.5 (C-13), 47.7
(C-7), 52.6 (6OCH3), 61.2 (C-9), 74.4 (C-20), 80.1 (C-6), 97.3 (C-5),
116.3 (C-2), 119.4 (C-1), 128.1 (C-11), 132.1 (C-12), 137.3 (C-3), 145.6
(C-4).; HRMS (TOF): Calcd. for C23H31NO4 [MþH]þ: 386.2325;
found: 386.2326.
4.1.2. General procedure for the preparation of 6-O-desmethyl-
orvinol derivatives (2a, 2b, 2c, 2d)
Lithium-aluminum hydride (1.1 g, 28.9 mmol) was suspended in
dry tetrahydrofuran (10 mL) under argon atmosphere. The sus-
pension was cooled to 0 C and dry carbon tetrachloride (0.74 mL,1.18 g, 7.7 mmol) was carefully added dropwise under stirring. A
solution of the corresponding orvinol derivative (1a, 1b, 1c, 1d,
1.92 mmol) in dry tetrahydrofuran (10 mL) was added dropwise
and the mixture was stirred under reflux for 36 h. The reaction
mixture was cooled to 0 C and diluted with tetrahydrofuran
(20 mL). Water (5 mL) was dropped in under vigorous stirring and
the suspension was filtered. The solid was washed with ethyl ace-
tate (3  20 mL) and dichloromethane (2  15 mL). The combined
organic phase was dried (Na2SO4) and the solvent was evaporated
under reduced pressure. The residue was dried in vacuum
(2  101 mbar, 16 h). The crude product was purified by column
chromatography on silica gel (Kieselgel: 100 g, eluent system: 1.
ethyl acetate e chloroform e 25% NH3 solution 70:30:1 (v/v/v), 2.
dichloromethaneemethanol 9:1 (v/v). Analytical data and detailed
NMR assignments for 2a, 2b and 2d are presented in Supporting
Information.
4.1.2.1. (5R,6R,7R,9R,13S,14S,20R)-(5a,7a)-4,5-Epoxy-18,19-dihydro-
3,6-dihydroxy-a,17-dimethyl -a-propyl-6,14-ethenomorphinan-7-
methanol (2c). Yield: 70%, mp. 127e128 C; TLC: Rf [A] ¼ 0.50, Rf
[C] ¼ 0.10, Rf [D] ¼ 0.22; 1H NMR (CDCl3): d ¼ 0.62 (m, 1H, 19-Hsyn),
0.89 (t, J ¼ 7.0 Hz, 3H, 20-CH3CH2CH2), 0.92 (m, 1H, 19-Hanti), 1.01
(dd, 2J8a,8b ¼ 13.0 Hz, 3J8a,7b ¼ 9.1 Hz, 1H, 8a-H), 1.06 (m, 1H, 18-
Hsyn), 1.36 (s, 3H, 20-CH3), 1.37 (m, 1H, 15-Heq), 1.38 (m, 2H,
CH3CH2CH2), 1.43 (m, 2H, CH3CH2CH2), 1.67 (m, 1H, 15-Hax), 1.83
(app t, 3J7b,8a ¼ 9.1 Hz, 1H, 7b-H), 1.87 (m, 1H, 18-Hanti), 2.14 (dd,
2J10a,10b ¼ 18.4 Hz, 3J10a,9a ¼ 6.3 Hz, 1H, 10a-H), 2.04 (m, 1H, 16-Hax),
2.25 (s, 3H, NCH3), 2.31 (dd, 2J16eq,16ax ¼ 11.5 Hz, 3J16eq,15ax ¼ 4.9 Hz,
1H, 16-Heq), 2.63 (ddd, 2J8b,8a ¼ 13.4 Hz, 3J8b,7b ¼ 10.3 Hz,
4J8b,19syn ¼ 3.0 Hz, 1H, 8b-H), 2.58 (d, 3J9a,10a ¼ 6.3 Hz, 1H, 9a-H),
3.01 (d, 2J10b,10a ¼ 18.4 Hz, 1H, 10b-H), 4.00 (s, 1H, 5b-H), 5.46 (br s,
1H, 20-OH), 6.03 (br s, 1H, 6-OH), 6.47 (d, 2J1,2 ¼ 8.1 Hz, 1H, 1-H),
6.77 (d, 2J2,1 ¼ 8.1 Hz, 1H, 2-H), 8.27 (br s, 1H, 3-OH); 13C NMR
(CDCl3): d ¼ 14.6 (20-CH3CH2CH2), 15.6 (CH3CH2CH2), 21.9 (C-10),
22.2 (C-18), 22.5 (20-CH3), 30.0 (C-19), 31.5 (C-8), 36.3 (C-15), 34.5
(C-14), 43.6 (CH3CH2CH2), 43.8 (NCH3), 45.1 (C-13), 45.2 (C-16), 45.8
(C-7), 61.3 (C-9), 75.6 (C-20), 76.7 (C-6), 96.2 (C-5), 116.8 (C-2), 119.4
(C-1), 127.9 (C-11), 132.4 (C-12), 137.1 (C-3), 145.8 (C-4); MS (ESI)m/
z: 400 [Mþ1]þ; HRMS (TOF): Calcd. for C24H33NO4 [MþH]þ:
400.2482; found: 400.2480.
Analytical data and detailed NMR assignments for 2d, 4, 5, 7 and
8 are presented in Supporting Information.
4.2. In vitro experiments
4.2.1. Chemicals
MgCl2 x 6H2O, EGTA, Tris-HCl, NaCl, GDP, the GTP analogue
GTPgS, were purchased from Sigma-Aldrich (Budapest, Hungary).
The highly selectiveMOR agonist enkephalin analogue DAMGOwas
obtained from Bachem Holding AG (Bubendorf, Switzerland). The
highly selective KOR agonist diphenethylamine derivative, HS665
[45] were kindly offered by Dr. Helmut Schmidhammer (University
of Innsbruck, Austria). The morphine analogues were provided by
ABX GmbH (Radeberg, Germany). The highly selective DOR agonist
Ile5,6-deltorphin II was synthesized in the Laboratory of Chemical
Biology group of the Biological Research Centre (Szeged, Hungary).
DAMGO, [Ile5,6]-deltorphin II and HS665 were dissolved in water,
morphine analogues were dissolved in ethanol and were stored in
1mM stock solution at20 C. The radiolabeled GTP analogue, [35S]
GTPgS (specific activity: 3.7  1013 Bq/mmol; 1000 Ci/mmol) was
purchased from Hartmann Analytic (Braunschweig, Germany). [3H]
DAMGO [46] (specific activity: 38.8 Ci/mmol), [3H]Ile5,6-deltorphin
II (specific activity: 19.6 Ci/mmol) and [3H]HS665 [47] (specific
activity: 13.1 Ci/mmol) were radiolabelled by the Laboratory of
Chemical Biology group in BRC (Szeged, Hungary). The
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from PerkinElmer (Boston, USA).
4.2.2. Animals
Formembrane homogenate preparationsmale and femaleWistar
rats and guinea pigs were used. Animals were housed in the local
animal house of BRC (Szeged, Hungary). All the animals were kept in
a temperature controlled room (21e24 C) under a 12:12 h light/dark
cycle and allowed free access to food and water. All housing and
experiments were conducted according to the European Commu-
nities Council Directives (86/606/ECC) and the Hungarian Act for the
Protection of Animals in Research (XXVIII.tv. 32.x). The total number
of animals as well as their suffering was minimized.
4.2.3. Preparation
A crude membrane fraction of Wistar rat and guinea pig brains
were prepared for ligand binding experiments according to Ref. [48]
with changes. After decapitation, brains were rapidly removed and
homogenised in 30 vol of ice-cold 50 mM TriseHCl (pH 7.4) buffer
with a teflon-glass homogeniser. After centrifugation at 40000g for
20 min at 4 C, the resulting pellet were suspended in 30 vol of the
same buffer and incubated for 30min at 37 C to remove endogenous
opioids. Centrifugation was then repeated as described above. The
final pellet were suspended in 5 vol of 50 mM TriseHCl (pH 7.4)
buffer and stored at 80 C. Membranes were thawed, diluted with
buffer and the resulting pellet were taken up in appropriate fresh
buffer and immediately used. For the [35S]GTPgS binding experi-
ments the final pellet of rat and guinea pig brain membrane ho-
mogenates were suspended in 5 vol of ice-cold TEM (Tris-HCl, EGTA,
MgCl2) and stored at 80 C for further use.
4.2.4. Receptor binding experiments
4.2.4.1. Competition binding experiments. In homologue displace-
ments using [3H]DAMGO, [3H]Ile5,6-deltorphin II or [3H]HS665 the
level of nonspecific binding was determined in the presence of
10 mM unlabeled naloxone (MOR and KOR) and HS665 (KOR), while
total binding was determined in the absence of cold ligand. The
incubation was followed by rapid filtration under vacuum (Brandel
M24R Cell Harvester; Brandel Harvesters), and washed three times
with 5mL ice-cold 50mMTris-HCl. The filtrationwas accomplished
throughWhatmanGF/C glass fibres (respectively). The radioactivity
of the filters was measured in UltimaGold MV aqueous scintillation
cocktail (Perkin Elmer, Waltham, MA) with Packard Tricarb 2300 TR
liquid scintillation counter (Perkin Elmer, Waltham, MA). The
competition binding assays were performed in duplicates and
repeated at least three times.
4.2.4.2. Functional [35S]GTPgS binding experiments. Rat and guinea
pig brain membranes (~10 mg of protein/tube) were incubated at
30 C for 60 min in TriseEGTA buffer (50 mM TriseHCl buffer, 3 mM
MgCl2, 1 mM EGTA, 100 mM NaCl, pH 7.4) containing 0.05 nM [35S]
GTPgS with increasing concentrations (1010-105 M) of opioid li-
gands tested in the presence of 30 mMGDP in a final volume of 1 mL
as previously described [49]. Total binding was measured in the
absence of test compounds, non-specific binding was determined in
the presence of 10 mM unlabeled GTPgS and subtracted from total
binding. The difference between total and non-specific binding
values represents basal activity. The reaction was terminated by
rapid filtration under vacuum (Brandel M24R Cell Harvester), and
Whatman GF/B glass fiber filters werewashed three times with 5mL
ice-cold 50mMTris-HCl (pH 7.4) buffer. The radioactivity of the dried
filters was detected in Ultima GoldTM MV aqueous scintillation
cocktail with Packard TriCarb 2300 TR liquid scintillation counter.
[35S]GTPgS binding experiments were performed in triplicates and
repeated three times.4.2.5. Data analysis
Experimental data were presented as means ± S.E.M. Points
were fitted with the professional curve fitting program, GraphPad
Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-
linear regression analysis. In the [35S]GTPgS binding assays the
‘Sigmoid dose-response’ fitting was used to establish the maximal
efficacy (Emax) of the receptors’ G-protein and the ligand potency
(EC50). Stimulation was given as percent of the specific [35S]GTPgS
binding observed over the basal activity, which was settled as 100%.
In the competition binding assays the ‘One site competition’
fitting was used to establish the equilibrium binding affinity (Ki
value). Inhibition was given as percent of the specific binding
observed.
4.3. In vivo experiments
After institutional ethical approval had been obtained (Institu-
tional Animal Care Committee of the Faculty of Medicine at the
University of Szeged), male Wistar rats (Charles River strain, Bio-
plan, Budapest, Hungary; 378 ± 5.1 g; n ¼ 6e8/group) were used in
the experiments. The animals were group-housed (4 animals/cage)
with free access to food and water, and with a 12:12 h light/dark
cycle. Animal suffering and the number of animals per group were
kept at a minimum; therefore, the drugs were administered in
cumulative doses in 30-min intervals (at 0th, 30th and 60th min),
and injections were repeated 7 days apart for the same animal, as in
our previous study [50].
The following drugs were applied for the in vivo nociceptive
studies: etorphine-hydrochloride (9) [25,51] eight 6,14-
ethenomorphinan derivatives synthesized as described earlier
[16e22,24], 2a and 1e, 1f, 2b, 2d, 4, 5, 7 as well as the new com-
pound 2c. The drugs were freshly diluted (0.01e10 mM) with
distilled water from the stock solutions and administered subcu-
taneously (s.c.) in a volume of 2 mL/kg.
Osteoarthritis was induced by injecting MIA (Sigma-Aldrich Ltd.
Budapest, Hungary; 1 mg/30 mL) into the tibiotarsal joint of the
right hind leg on two consecutive days. MIA treatments were given
to gently restrained conscious animals, using a 27-gauge needle,
without anesthesia so as to exclude any drug interaction. These
injections did not elicit signs of major distress. Within 14 days MIA
had consistently been shown to cause severe end-stage cartilage
destruction resulting in osteoarthritis-like joint pain accompanied
with moderate edema [50,52,53]. The observer was blind to the
drug treatment administered.
4.3.1. Behavioral nociceptive testing
The threshold for withdrawal from mechanical stimulation to
the plantar aspect of the hindpaws was assessed using a dynamic
plantar aesthesiometer (Ugo Basile, Comerio, Italy), which consists
of an elevated wire mesh platform to allow access to the ventral
surface of the hindpaws. Prior to baseline testing, each rat was
habituated to a testing box for at least 20 min. Measurements were
done with a straight metal needle (diameter 0.5 mm) that exerts an
increasing upward force at a constant rate (6.25 g/s) with a
maximum cut-off force of 50 g over an 8 s period. Themeasurement
was stopped when the paw was withdrawn, and the results were
expressed as paw withdrawal thresholds in grams.
4.3.2. Experimental paradigm
After MIA injections, baseline pain thresholds (2 times with
15 min interval) were determined 14 days later and their means
provided the baseline value.
Cumulative-dosing procedure was applied (Table 4). The control
group received distilled water. In the positive control group, ani-
mals were treated with 9 (0.1, 0.3, and 1.0 nmol/kg). The higher
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3.0 nmol/kg) but 3.0 nmol/kg dose induced catatonia and respira-
tory depression in 100% of the animals, thus we determined the
maximum dose as 1 nmol/kg. Response latencies were measured at
15 min intervals and the increasing doses of the drugs (three doses)
were administered following two recordings. After the highest dose
injection the pain threshold was assessed in every 15 min for 1 h,
then hourly at the second and third hour to determine the time
course of drug effects. Although, the motor behavior and general
status of the animals were not investigated and quantified sys-
tematically, altered behavior (excitation, flaccidity or motor weak-
ness) or any signs of opioid overdose (catatonia or respiratory
depression) were not observed.
4.3.3. Statistical analysis
Data are presented asmeans± SEM. Data sets were examined by
repeated measures of ANOVA. Post hoc comparisons were carried
out with the Fisher LSD test. A p value lower than 0.05 was
considered significant. The mean paw withdrawal thresholds ob-
tained 15 and 30 min after the injections (calculated after the in-
dividual drug injections) were used for linear regression analysis to
determine the effective dose 30 (ED30) values with 95% confidence
intervals. Mean of 50 g would mean the complete relief of hyper-
algesia, while mean of control value (29 g) means the zero effects,
thus the difference (21 g) is the possible maximal effect. ED30 is
equivalent to the dose that yielded 30% difference (7 g) in the paw
withdrawal threshold compared to the baseline (pretreatment)
values. Data analyses were performed with the STATISTICA (Sta-
tistica Inc., Tulsa, Oklahoma, USA) and GraphPad Prism 4.0
(GraphPad Softwre Inc. La Jolla, CA, US) softwares.
4.4. In silico studies
4.4.1. Molecular docking
The ligands were flexibly docked to the experimentally solved
active and inactive states of MOR (http://www.rcsb.org, pdb codes
5c1m and 4dkl for the active and inactive receptor states, respec-
tively). The receptor structures were kept rigid. Due to the known
limitation of the docking algorithm i.e. the rings are kept rigid
during the calculation, 10 different conformations were generated
bymolecular dynamics to emulate the conformational flexibility for
aliphatic rings in accordance with experimental findings [54]. The
10 conformations and the initial energyminimized conformer were
provided for docking for each ligand. Docking calculations were
performed by the program PSOVINA [55], a variant of the formerly
released VINA [56]. Coordinate files were converted to pdbqt
format by AutoDock Tools [57] or PSOVINA. Docking box center was
set to the geometric center of the ligands in the crystals. Due to the
impact of the size of the docking box on the docking pose, namely
on the set of interacting receptor atoms, the box size was specif-
ically determined for each ligand [58] using the radius of giration
(Rg) of the minimum energy conformer calculated by Open Babel.
PSOVINA was used with default parameters, albeit docking was
repeated 5 times instead of increased exhaustiveness parameter
[59] and the lowest energy docking poses was kept for each ligand.
4.4.2. Analysis of docking results
The selected poses were analysed by the program BINANA [43]
to extract the interacting ligand-receptor atom pairs, the docking
energies and the energy contributions belonging to the specific
atom pairs. Stabilizing or destabilizing assignments for the ligand-
receptor contacts based on the method Soboljev et al. [44]. Analysis
of the docking energies and the interacting receptor atoms were
performed by principal component analysis (PCA) and multiple
correspondence analysis (MCA), respectively, using programpackages of the R programming environment v. 3.5.1 [60]. Calcu-
lations were performed by the PCA and MCA moduls of the R
package “FactoMineR” [61]. Results were visualized using package
“factoextra” [62]. For 3D visualization packages “rgl” and “pca3d”
were used [63,64]. Docking calculations were performed on a Linux
cluster running Rocks 6.2 clustermanagement program and CentOS
6.6 operation system and on the PRACE/NIIF cluster, and the ana-
lyses in Linux Mint 18.1 using in house bash and R scripts.
4.4.3. Generation of the ligand conformations
Open Babel v. 2.4.1 program package [65] was used in a two-step
manner: 1. conformers were generated with the “–score energy”
option to avoid high energy structures, 2. conformers were further
transformed with “–rings” option to allow ring flexibility using
MMFF94s force field.
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bPh beta-phenylethyl group, beta-phenethyl group,
CH2CH2Ph
CPM cyclopropylmethyl group
DAMGO Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol
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EGTA ethyleneglycol-tetraacetate
GDP guanosine diphosphate
GTP guanosine triphosphate
KOR k-opioid receptor
MIA monosodium iodoacetate
MOR m-opioid receptor
S.E.M. standard error of means
tris-HCl tris-(hydroxymethyl)-aminomethane hydrochloride.
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